FIELD: medicine; bioengineering.
SUBSTANCE: are offered variants of antibodies, specifically recognizing two regions of peptide β-A4, characterised by amino-acid residual list. The first region of recognised peptide contains amino-acid sequence AEFRHDSGY or fragment thereof, while the second region contains amino-acid sequence VHHQKLVFFAEDVG or fragment thereof. Described are nucleic acid molecules coding molecules of antibodies, offered in invention, vectors and hosts containing specified nucleic acid molecules. Discovered are methods of antibodies production and optimisation, pharmaceutical compositions based on specified antibodies and method of production thereof, as well as antibodies-based set and various applications of antibodies. Invention application provides high-avidity antibodies of peptide β-A4 that can be applied for diagnostics of various peptide β-A4 mediated diseases.
EFFECT: efficient application of compositions.
29 cl, 15 dwg, 10 tbl, 16 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODY TO AMYLOID BETA | 2013 |
|
RU2651486C2 |
HUMANISED ANTIBODY TO BETA AMYLOID | 2007 |
|
RU2498999C2 |
APPLICATION OF ANTIBODY AGAINST AMYLOID-BETA IN CASE OF EYE DISEASES | 2008 |
|
RU2571859C2 |
HUMANIZED ANTIBODY TO BETA AMYLOID | 2013 |
|
RU2668161C2 |
HUMANISED ANTIBODIES TO AMYLOID BETA | 2008 |
|
RU2567151C2 |
USING ANTI-AMYLOID BETA ANTIBODY IN OPHTHALMIC DISEASES | 2008 |
|
RU2542967C2 |
HUMANISED ANTIBODY | 2008 |
|
RU2538709C2 |
USING ANTI-AMYLOID BETA ANTIBODY IN OPHTHALMIC DISEASES | 2008 |
|
RU2604181C2 |
SAFE AND FUNCTIONAL HUMANIZED ANTIBODIES | 2011 |
|
RU2607368C2 |
HUMAN ANTI-CD38-ANTIBODIES AND THEIR APPLICATION | 2005 |
|
RU2402568C2 |
Authors
Dates
2008-12-20—Published
2003-02-20—Filed